J & J to Pay More Than $1 Billion For Wrongful Marketing of Risperdal

In order to resolve a civil investigation into the marketing of Risperdal for unapproved uses, Johnson & Johnson will pay more than $1 billion to the U.S. Government and states. Negotiations over possible criminal pleas by J & J are ongoing.
Read more                          Discuss → 


Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.